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It has been brought to our attention that there were a number
of typographical errors in one section of our recent article [1]
published in December 2005.
All corrections apply to the section entitled, ‘Biochemical
rationale; Eicosanoids: cyclo-oxygenase pathway’.
The second paragraph should read:
The usual substrate for the COX isozymes is the n6 LC PUFA
arachidonic acid (AA; C20:4n-6). Eicosapentaenoic acid
(EPA; C20:5n-3), which is present in fish oil, differs from AA
only by the presence of its n3 bond (Fig. 1).
The last sentence of the third paragraph should read:
Thus, the net effect of fish oil is to reduce the production of
proinflammatory and pro-thrombotic eicosanoids (PGE2 and
TXA2, respectively) but not the vascular patency factor
prostacyclin (PGI2; Fig. 2).
Finally, the first 20-Carbon fatty acid homologue pictured in
Figure 1 (C20:3 n-9) is eicosatrienoic acid, rather than oleic
acid.
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